West Pharmaceutical Services Inc. Files Definitive Proxy Statement

Ticker: WST · Form: DEF 14A · Filed: Mar 13, 2024 · CIK: 105770

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, Executive Compensation, Corporate Governance, Shareholder Meeting

TL;DR

<b>West Pharmaceutical Services Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023.</b>

AI Summary

WEST PHARMACEUTICAL SERVICES INC (WST) filed a Proxy Statement (DEF 14A) with the SEC on March 13, 2024. Filing is a Definitive Proxy Statement (DEF 14A) filed on March 13, 2024. The report covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 530 Herman O. West Drive, Exton, PA 19341. West Pharmaceutical Services Inc. was formerly known as West Co Inc, with a name change on April 5, 1999. The filing includes data related to equity awards and pension adjustments for PEO and Non-PEO members for the years 2023 and 2022.

Why It Matters

For investors and stakeholders tracking WEST PHARMACEUTICAL SERVICES INC, this filing contains several important signals. This filing provides shareholders with crucial information regarding executive compensation, board nominations, and other governance matters to be voted on at the upcoming annual meeting. Understanding the details within this proxy statement is essential for shareholders to make informed voting decisions and assess the company's alignment with shareholder interests.

Risk Assessment

Risk Level: low — WEST PHARMACEUTICAL SERVICES INC shows low risk based on this filing. The filing is a routine DEF 14A, indicating standard corporate governance disclosures rather than immediate financial or operational concerns.

Analyst Insight

Shareholders should review the executive compensation details and any proposed governance changes to make informed voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did WEST PHARMACEUTICAL SERVICES INC file this DEF 14A?

WEST PHARMACEUTICAL SERVICES INC filed this Proxy Statement (DEF 14A) with the SEC on March 13, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by WEST PHARMACEUTICAL SERVICES INC (WST).

Where can I read the original DEF 14A filing from WEST PHARMACEUTICAL SERVICES INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by WEST PHARMACEUTICAL SERVICES INC.

What are the key takeaways from WEST PHARMACEUTICAL SERVICES INC's DEF 14A?

WEST PHARMACEUTICAL SERVICES INC filed this DEF 14A on March 13, 2024. Key takeaways: Filing is a Definitive Proxy Statement (DEF 14A) filed on March 13, 2024.. The report covers the fiscal year ending December 31, 2023.. The company's principal executive offices are located at 530 Herman O. West Drive, Exton, PA 19341..

Is WEST PHARMACEUTICAL SERVICES INC a risky investment based on this filing?

Based on this DEF 14A, WEST PHARMACEUTICAL SERVICES INC presents a relatively low-risk profile. The filing is a routine DEF 14A, indicating standard corporate governance disclosures rather than immediate financial or operational concerns.

What should investors do after reading WEST PHARMACEUTICAL SERVICES INC's DEF 14A?

Shareholders should review the executive compensation details and any proposed governance changes to make informed voting decisions. The overall sentiment from this filing is neutral.

How does WEST PHARMACEUTICAL SERVICES INC compare to its industry peers?

West Pharmaceutical Services operates in the surgical and medical instruments & apparatus industry.

Are there regulatory concerns for WEST PHARMACEUTICAL SERVICES INC?

The filing is made under the Securities Exchange Act of 1934, specifically Form DEF 14A, which pertains to the solicitation of proxies.

Industry Context

West Pharmaceutical Services operates in the surgical and medical instruments & apparatus industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Form DEF 14A, which pertains to the solicitation of proxies.

What Investors Should Do

  1. Review the detailed executive compensation tables for 2023.
  2. Examine the board of directors' recommendations and any shareholder proposals.
  3. Note the dates for the upcoming annual shareholder meeting.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document and does not represent a change from previous filings in terms of its nature.

Filing Stats: 4,316 words · 17 min read · ~14 pages · Grade level 18.6 · Accepted 2024-03-13 08:31:16

Key Financial Figures

Filing Documents

Executive Compensation Program Design

Executive Compensation Program Design 47 Factors Used in the Compensation Process 49 Business Segment Group 51 Impact of Business Results on our 2023 Incentive Plans 56 Incentive Compensation: Important Facts about Our Incentive Targets 52 Our Annual Incentive Compensation 53 Financial Measures and Adjustments 54 2023 Consolidated Performance 55 Our Long-Term Equity Incentive Compensation 56 2023 Compensation Decisions 57 Other Compensation Practices 59 Compensation Tables 62 2023 Summary Compensation 62 2023 Grant of Plan-Based Awards 64 Outstanding Equity Awards at Year-End 2023 65 2023 Option Exercises and Stock Vested 66 2023 Pension Benefits 67 2023 Nonqualified Deferred Compensation 67 Payments on Disability 68 Table of Contents Payments on Death 68 Estimated Payments Following Termination 69 Estimated Additional Severance Payments 69 Payments on Termination in Connection with a Change-in-Control 70 CEO Pay Ratio 73 Pay Versus Performance 73 Proposal 2 — Advisory Vote to Approve Named Executive Officer Compensation 77 Independent Auditors and Fees 78 Audit Committee Report 79 Proposal 3 — Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Transaction Requirement 80 Proposal 4 — Amend and Restate Our Amended and Restated Articles of Incorporation to Eliminate Supermajority Amendment Requirement 81 Proposal 5 — Ratification of the Appointment of PricewaterhouseCoopers LLP as Our Independent Registered Public Accounting Firm 82 Proposal 6 — Shareholder Proposal Entitled " Simple Majority Vote " 83 Voting and Other Information 85 APPENDIX 1 - Proposed Changes to Amended and Restated Articles of Incorporation A-1 Table of Contents PROXY SUMMARY Proxy Summary Below is a summary of important information you will find in this Proxy Statement. This summary does not contain all the inf

Executive Compensation Program Features

Executive Compensation Program Features Strong linkage between pay and performance and support by shareholders regarding our performance metrics, targets and goals as evidenced by a 95.5% shareholder Say-on-Pay approval rate of our executive compensation program Competitive total direct compensation ("TDC"), which is the sum of an officer's base salary, short-term incentive target and long-term incentive target, targeted at the median level and appropriately adjusted by our Compensation Committee based on individual performance, skills and experience Formulaic Annual Incentive Plan ("AIP") based on EPS, net sales and Operating Cash Flow ("OCF") is intended to encourage Management to improve shareholder value in day-to-day decision making Challenging long-term incentive ("LTI") plan utilizing stock options and performance share units based upon return on invested capital ("ROIC") and sales consolidated annual growth rate ("CAGR") to ensure long-term profitable growth and alignment with shareholders' interests Use of two comparator groups to benchmark competitive pay standards to ensure Company can attract and retain the best talent Robust share ownership guidelines for all officers and directors Standard Change in Control ("CIC") agreements for our current officers containing double trigger provisions requiring termination of the executive following a CIC before payments are made; payments are reduced if excise tax threshold is exceeded Strong incentive compensation recovery (clawback) that exceeds legal requirements, anti-hedging and anti-pledging policies Rigorous use of realizable pay analysis, performance metric difficulty analysis and similar tools to ensure our compensation programs remain linked to performance and consistent with Board expectations Active engagement with shareholders throughout the year regarding executive pay and Company performance issues

Executive Compensation Actions & Results

Executive Compensation Actions & Results Appointed a new Compensation Committee Chair, aligning to best practices of rotating Board members to provide new insight and leadership Reviewed and approved revised Incentive Compensation Recovery policies for Executive Officers and Non-Officers, in adherence with SEC rules mandated by Dodd-Frank Act, while also reaffirming and enhancing discretionary recovery policies that go beyond what is required by law Strengthened Rule 10b5-1 trading plan rules, policies and procedures and provided education to executives on insider trading Reaffirmed West's commitment to a pay-for-performance philosophy that aligns executives' incentive compensation with Company performance and stakeholder interests on both a short and long-term basis, while mitigating excessive risk Confirmed the ongoing use of a two-comparator group approach for executive and director pay and pay-for-performance benchmarking; conducted a thorough review of the Business Segment Comparator Group resulting in the removal of CONMED in 2024 Executed compensation payouts to our corporate executives at 121.5% of target amount based on 2023 AIP performance payout levels of 114.0% for EPS, 84.6% for Net Sales and 180.7% for OCF Awarded LTI plan PSUs for the 2021-23 period at 107.64% of target amount based on a CAGR performance payout level of 56.81% and an ROIC payout level of 50.83% 6 | 2024 Annual Meeting and Proxy Statement Table of Contents ELECTION OF DIRECTORS q Election of Directors Director Nominations, Skills and Criteria Candidates for nomination to our Board are recommended by the Nominating and Corporate Governance Committee ("NCGC") in accordance with the NCGC's charter, our Articles, our Bylaws, and our Corporate Governance Principles. All persons recommended for nomination to our Board, regardless of the source of the recommendation, are evaluated by this Committee with the Board determining the final slate of nominees. The Board and the

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing